Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cardiac Surgery With Cardiopulmonary Bypass Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass

NCT02037555
View directory record Official record
Conditions
Cardiac Surgery, Cardiopulmonary Bypass
Interventions
AT-III (Human), Placebo
Biological · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
41
States / cities
Orange, California • San Francisco, California • Stanford, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Jul 22, 2026, 2:05 AM EDT
Completed No phase listed Observational

Heparin Management During Cardiopulmonary Bypass in Children

NCT00146653
View directory record Official record
Conditions
Primary Condition: Heart Defects Requiring Surgery With CPB
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Up to 6 Months
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Jul 22, 2026, 2:05 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass Surgery

NCT07646210
View directory record Official record
Conditions
Advanced Heart Failure, Ischemic Heart Failure
Interventions
HiCM-188 Cells
Drug
Lead sponsor
HELP Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 22, 2026, 2:05 AM EDT
Active, not recruiting Phase 1 Interventional

Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP)

NCT04236479
View directory record Official record
Conditions
Congenital Heart Disease (CHD)
Interventions
BM-MSC
Biological
Lead sponsor
Catherine Bollard
Other
Eligibility
Up to 6 Months
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 22, 2026, 2:05 AM EDT
Terminated Phase 2 Interventional

CTI-01 (Ethyl Pyruvate) Safety and Complication Prevention in Cardiac Surgery Patients on Cardiopulmonary Bypass (CPB)

NCT00107666
View directory record Official record
Conditions
Coronary Disease, Heart Valve Diseases
Interventions
CTI-01 (ethyl pyruvate)
Drug
Lead sponsor
Critical Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Laguna Hills, California • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2006 · Synced Jul 22, 2026, 2:05 AM EDT
Completed No phase listed Observational

Risk of Developing Antibodies to Heparin-PF4 After Heart Surgery

NCT00237328
View directory record Official record
Conditions
Thrombosis
Interventions
Heparin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
4
States / cities
Rochester, Minnesota • Chapel Hill, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2013 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB

NCT03122730
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
VentaProst
Combination Product
Lead sponsor
Aerogen Pharma Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Not applicable Interventional Results available

Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery

NCT01245595
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Day to 18 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass

NCT02025621
View directory record Official record
Conditions
Coronary Artery Bypass Grafting, Mitral Valve Surgery, Low Cardiac Output Syndrome
Interventions
Levosimendan, Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
49
States / cities
Burlington, Alabama • Huntsville, Alabama • Sacramento, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Jul 22, 2026, 2:05 AM EDT
Terminated Phase 3 Interventional

Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery

NCT00458276
View directory record Official record
Conditions
Heart Diseases, Hypertension, Pulmonary
Interventions
tezosentan, placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Stanford, California • New York, New York • Durham, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Jul 22, 2026, 2:05 AM EDT
Completed No phase listed Observational

Impact of Pre-operative Steroids on Adrenal Insufficiency

NCT02956707
View directory record Official record
Conditions
Adrenal Insufficiency Neonatal
Interventions
No pre-operative steroids
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 60 Days
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Jul 22, 2026, 2:05 AM EDT
Terminated Phase 2 Interventional Results available

Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery

NCT01336959
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
BCT197 Part A, Placebo, BCT197 Part B
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Orange, California • Saginaw, Michigan • Lincoln, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Jul 22, 2026, 2:05 AM EDT
Withdrawn Phase 2 Interventional

Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery

NCT03446599
View directory record Official record
Conditions
Vasoplegia, Hypotension, Coronary Artery Disease, Cardiac Valve Disease
Interventions
Hydroxocobalamin, Methylene Blue, Normal saline
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction.

NCT02836899
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Nitric Oxide, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jul 22, 2026, 2:05 AM EDT
Recruiting No phase listed Observational

Evaluation of Plasma Renin Concentrations in Cardiac Surgery

NCT06895213
View directory record Official record
Conditions
Cardiac Surgery With Cardiopulmonary Bypass
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 22, 2026, 2:05 AM EDT
Withdrawn Phase 2 Interventional

Effects of Nitric Oxide on the Endothelium During Hemolysis.

NCT03748082
View directory record Official record
Conditions
Endothelial Dysfunction, Hemolysis Intravascular, Cardiovascular Diseases, Cardiovascular Risk Factor
Interventions
Nitric Oxide, Reactive Hyperemia Index, Endothelial Cells Collection
Drug · Diagnostic Test · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Phase 3 Interventional

Angiomax in Patients With HIT/HITTS Type II Undergoing CPB

NCT00079508
View directory record Official record
Conditions
Cardiovascular Disease, Coronary Artery Bypass Surgery
Interventions
Angiomax (bivalirudin)
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 9, 2011 · Synced Jul 22, 2026, 2:05 AM EDT
Withdrawn Phase 3 Interventional

A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing Delirium After Heart Surgery

NCT00464763
View directory record Official record
Conditions
Delirium
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
11
States / cities
Loma Linda, California • Towson, Maryland • Grand Blanc, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Phase 3 Interventional

Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass

NCT00048308
View directory record Official record
Conditions
Cardio-pulmonary Bypass, Coronary Artery Bypass Graft
Interventions
pexelizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
168
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Phase 3 Interventional

Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)

NCT00079586
View directory record Official record
Conditions
Cardiovascular Disease, Coronary Artery Bypass Surgery
Interventions
Heparin, Bivalirudin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 4, 2012 · Synced Jul 22, 2026, 2:05 AM EDT
Completed No phase listed Observational

Cardiac Deformation: Correlation With Conventional Echocardiographic Hemodynamic Variables (An Intraoperative Study)

NCT00874991
View directory record Official record
Conditions
Cardiac Disease
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Phase 3 Interventional

ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

NCT05746559
View directory record Official record
Conditions
Chronic Kidney Disease, CKD, Cardiac Disease, Cardiopulmonary Bypass
Interventions
Placebo, Ravulizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
Orange, California • San Francisco, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 22, 2026, 2:05 AM EDT
Recruiting Phase 3 Interventional

Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass

NCT06702553
View directory record Official record
Conditions
Nitric Oxide, Cardiac Surgery, Cardiopulmonary Bypass, Adult Patients Undergoing Cardiovascular Surgery With Cardiopulmonary Bypass
Interventions
Nitric Oxide Gas, Standard Care Arm
Drug
Lead sponsor
Xijing Hospital
Other
Eligibility
18 Years and older
Enrollment
3,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Phase 3 Interventional

Safety and Hemostatic Efficacy of Fibrin Sealant Vapor Heated, Solvent/Detergent Treated (FS VH S/D) Compared With Currently Licensed TISSEEL VH Fibrin Sealant in Subjects Undergoing Cardiac Surgery

NCT00161733
View directory record Official record
Conditions
Cardiac Surgery Requiring Cardiopulmonary Bypass and Median Sternotomy, Cardiopulmonary Bypass, Sternotomy
Interventions
Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D), TISSEEL VH fibrin sealant
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years and older
Timeline
2002 – 2004
U.S. locations
22
States / cities
Phoenix, Arizona • Orange, California • Gainesville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Jul 22, 2026, 2:05 AM EDT